Titel niet beschikbaar

door Horning, Sandra
Gepubliceerd in 2006

Allied in Achieving the Best-Quality Cancer Care

door Horning, Sandra
Gepubliceerd in 2006

Hodgkin lymphoma a comprehensive update on diagnostics and clinics /

door Engert, Andreas., Horning, Sandra J.
Gepubliceerd in 2011

Immunoglobulin G Fc Receptor FcγRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma

door Weng, Wen-Kai, Negrin, Robert S., Lavori, Philip, Horning, Sandra J.
Gepubliceerd in 2010

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience

door Chen, Andy I., McMillan, Alex, Negrin, Robert S., Horning, Sandra J., Laport, Ginna G.
Gepubliceerd in 2008

Dynamic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr Virus Antigens in Patients With Epstein-Barr Virus-Negative Hodgkin’s Disease

door Kohrt, Holbrook, Johannsen, Alexandre, Hoppe, Richard, Horning, Sandra J., Rosenberg, Saul A., Advani, Ranjana, Lee, Peter P.
Gepubliceerd in Oncol Res (2009)

Stage I-IIA Non-Bulky Hodgkin Lymphoma. Is Further Distinction Based on Prognostic Factors Useful? The Stanford Experience

door Advani, Ranjana H., Hoppe, Richard T, Maeda, Lauren S., Baer, David M., Mason, Joseph, Rosenberg, Saul A, Horning, Sandra J
Gepubliceerd in 2010

Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials

door Koontz, Michael Zach, Horning, Sandra J., Balise, Raymond, Greenberg, Peter L., Rosenberg, Saul A., Hoppe, Richard T., Advani, Ranjana H.
Gepubliceerd in 2013

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial

door Advani, Ranjana H., Hong, Fangxin, Horning, Sandra J., Kahl, Brad S., Manola, Judith, Swinnen, Lode J., Habermann, Thomas M., Ganjoo, Kristen
Gepubliceerd in 2011

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

door Horning, Sandra J., Juweid, Malik E., Schöder, Heiko, Wiseman, Gregory, McMillan, Alex, Swinnen, Lode J., Advani, Ranjana, Gascoyne, Randy, Quon, Andrew
Gepubliceerd in 2010

Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease

door Tseng, Diane, Rachakonda, Leelanand P, Su, Zheng, Advani, Ranjana, Horning, Sandra, Hoppe, Richard T, Quon, Andrew, Graves, Edward E, Loo, Billy W, Tran, Phuoc T
Gepubliceerd in 2012

A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

door Greenwald, Daniel R, Li, Hailun, Luger, Selina M, Go, Ronald S, King, David, Patel, Taral, Gascoyne, Randy D, Kolesar, Jill, Kahl, Brad S, Horning, Sandra
Gepubliceerd in 2013

Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Group Study (E2404)

door Ganjoo, Kristen, Hong, Fangxin, Horning, Sandra J., Gascoyne, Randy D., Natkunam, Yasodha, Swinnen, Lode J., Habermann, Thomas M., Kahl, Brad S., Advani, Ranjana H.
Gepubliceerd in 2013

A Phase II Trial of R-CHOP Followed by Radioimmunotherapy for Early Stage (Stages I/II) Diffuse Large B-Cell Non-Hodgkin Lymphoma: ECOG3402

door Witzig, Thomas E., Hong, Fangxin, Micallef, Ivana N., Gascoyne, Randy D., Dogan, Ahmet, Wagner, Henry, Kahl, Brad S., Advani, Ranjana H., Horning, Sandra J.
Gepubliceerd in Br J Haematol (2015)

Fc gamma receptor 3A and 2A polymorphisms do not predict response to rituximab in follicular lymphoma

door Kenkre, Vaishalee P., Hong, Fangxin, Cerhan, James R., Lewis, Marcia, Sullivan, Leslie, Williams, Michael E., Gascoyne, Randy D., Horning, Sandra J., Kahl, Brad S.
Gepubliceerd in Clin Cancer Res (2015)

Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG...

door Hochster, Howard, Weller, Edie, Gascoyne, Randy D., Habermann, Thomas M., Gordon, Leo I., Ryan, Theresa, Zhang, Lijun, Colocci, Natalia, Frankel, Stanley, Horning, Sandra J.
Gepubliceerd in 2009

Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell...

door Smith, Mitchell R., Li, Hailun, Gordon, Leo, Gascoyne, Randy D., Paietta, Elisabeth, Forero-Torres, Andres, Kahl, Brad S., Advani, Ranjana, Hong, Fangxin, Horning, Sandra J.
Gepubliceerd in 2012

Developing Standards for Breakthrough Therapy Designation in Oncology

door Horning, Sandra J., Haber, Daniel A., Selig, Wendy K.D., Ivy, S. Percy, Roberts, Samantha A., Allen, Jeff D., Sigal, Ellen V., Sawyers, Charles L.
Gepubliceerd in 2013

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

door Chang, Julie E., Li, Hailun, Smith, Mitchell R., Gascoyne, Randy D., Paietta, Elisabeth M., Yang, David T., Advani, Ranjana H., Horning, Sandra J., Kahl, Brad S.
Gepubliceerd in 2014

Response-Adapted Therapy for Aggressive non-Hodgkin's Lymphomas based on early [18F] FDG-PET Scanning: ECOG-ACRIN Cancer Research Group Study (E3404)

door Swinnen, Lode J., Li, Hailun, Quon, Andrew, Gascoyne, Randy, Hong, Fangxin, Ranheim, Erik A., Habermann, Thomas M., Kahl, Brad S., Horning, Sandra J., Advani, Ranjana H.
Gepubliceerd in Br J Haematol (2015)